Literature DB >> 23384012

When more is needed: the utility of the frontotemporal dementia scale in ALS.

Sharpley Hsieh1, Patricia Lillo, Matthew C Kiernan, John R Hodges, Eneida Mioshi.   

Abstract

ALS and frontotemporal dementia (FTD) utilize different functional rating scales: the ALSFRS-R assesses physical disability whereas the Frontotemporal Dementia Rating Scale assesses behavioural and functional impairment to produce an index of dementia staging. To better consider the applicability of the FRS in an ALS population, 130 patient-carer dyads were investigated. Scores on the ALSFRS-R and FRS were not significantly correlated (r(s) = 0.12, p > 0.10). Furthermore, patients with mild physical disability may rate as severe on the FRS; conversely, individuals who are severely physically disabled may exhibit very few behavioural symptoms. Measures typically used in ALS studies do not fully encapsulate the range of clinical symptoms, particularly from a behavioural perspective.

Entities:  

Mesh:

Year:  2013        PMID: 23384012     DOI: 10.3109/21678421.2013.764899

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  2 in total

1.  Measuring disease progression in corticobasal syndrome.

Authors:  Nancy Huang; Michael Hornberger; John R Hodges; James R Burrell
Journal:  J Neurol       Date:  2014-06-04       Impact factor: 4.849

2.  Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort.

Authors:  Georgia Peakman; Lucy L Russell; Rhian S Convery; Jennifer M Nicholas; John C Van Swieten; Lize C Jiskoot; Fermin Moreno; Raquel Sanchez-Valle; Robert Laforce; Caroline Graff; Mario Masellis; Maria Carmela Tartaglia; James B Rowe; Barbara Borroni; Elizabeth Finger; Matthis Synofzik; Daniela Galimberti; Rik Vandenberghe; Alexandre de Mendonça; Chris R Butler; Alex Gerhard; Simon Ducharme; Isabelle Le Ber; Fabrizio Tagliavini; Isabel Santana; Florence Pasquier; Johannes Levin; Adrian Danek; Markus Otto; Sandro Sorbi; Jonathan D Rohrer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-08-05       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.